Instil Bio to Present at Upcoming Investor Conferences in November

Rhea-AI Summary

Instil Bio, Inc. (Nasdaq: TIL) announced its participation in two investor conferences in November 2021. The Cowen 5th Annual IO Next Summit is scheduled for November 15, 2021, from 4:45 PM to 5:05 PM ET, with a live session link available. The Jefferies Global Healthcare Conference will be held on November 18, 2021, at 3:00 AM ET, also offering a live session link. An archived replay of both events will be accessible on the company's website for 90 days post-presentation. Instil is dedicated to developing TIL therapies targeting various cancers.

DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in November:

Cowen 5th Annual IO Next Summit
Monday, November 15, 2021
Session Time: 4:45 PM – 5:05 PM ET
Live Session Link: https://wsw.com/admin/link/presenter.aspx?418616172

Jefferies Global Healthcare Conference (London)
Thursday, November 18, 2021
Session Time: 3:00 AM ET
Session Link: https://wsw.com/webcast/jeff201/til/1696446/.
An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

Both sessions can also be accessed by visiting the News & Events section of the Instil Bio website at www.instilbio.com.

About Instil Bio

Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.

Contacts:

Investor Relations
1-972-499-3350
investor.relations@instilbio.com
www.instilbio.com

Brendan Payne
Stern Investor Relations
1-212-362-1200
brendan.payne@sternir.com 

FAQ

When is Instil Bio participating in the Cowen 5th Annual IO Next Summit?

Instil Bio will participate in the Cowen 5th Annual IO Next Summit on November 15, 2021, from 4:45 PM to 5:05 PM ET.

What is the date and time of the Jefferies Global Healthcare Conference for Instil Bio?

The Jefferies Global Healthcare Conference for Instil Bio will take place on November 18, 2021, at 3:00 AM ET.

How can I access the live sessions for Instil Bio's investor conferences?

The live sessions for Instil Bio's investor conferences can be accessed via the provided session links in the press release.

Where can I find the archived replays of Instil Bio's conference presentations?

Archived replays of Instil Bio's conference presentations will be available on the company's website for approximately 90 days after the events.

What is Instil Bio's focus in biopharmaceuticals?

Instil Bio focuses on developing tumor infiltrating lymphocyte (TIL) therapies for cancer treatment.